Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Executive VP, Global R&D | May 17, 2022 | May 19, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date May 17, 2022 · Filed May 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,386.514 |
Reported balance
After 2022-05-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-05-17 · Sale · Disposed 130,000 · Balance 1,386.514 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.185 to $8.240, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. F3: The shares held by the reporting person prior to the sale reported in this Form 4 included 5,300 Ordinary Shares previously issued to the reporting person in exempt transactions in connection with the settlement of certain equity-based awards granted to the reporting person, which were inadvertently omitted from the reporting person's previously reported amount of securities beneficially owned. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.185 to $8.240, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: The shares held by the reporting person prior to the sale reported in this Form 4 included 5,300 Ordinary Shares previously issued to the reporting person in exempt transactions in connection with the settlement of certain equity-based awards granted to the reporting person, which were inadvertently omitted from the reporting person's previously reported amount of securities beneficially owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2020 Filed Feb 18, 2020 12:23 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 17,850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-009879 · doc4.xml · nonDerivative · entry 2 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,532.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 12:23 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 5,353 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-009879 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,682.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 12:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 17,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009049 · doc4.xml · derivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,850 Underlying: Ordinary Shares · 17,850 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 14, 2020. F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 14, 2020. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 11:57 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 5,544 | $12.27 | $68,024.88 |
DisclosureSEC source: 0001209191-20-008164 · doc4.xml · nonDerivative · entry 2 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,329.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. Read SEC document |
| February 09, 2020 Filed Feb 11, 2020 11:57 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 16,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008164 · doc4.xml · derivative · entry 3 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,241 Underlying: Ordinary Shares · 16,120 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022. F5 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2020 Filed Feb 11, 2020 11:57 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 16,120 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-008164 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,873.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 11:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 4,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-000005 · doc4.xml · derivative · entry 3 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,640 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on July 1, 2014, with 4,640 vesting on each of December 31, 2018 and December 31, 2019. F6 · derivative.expiration_date: Restricted share units were granted on July 1, 2014, with 4,640 vesting on each of December 31, 2018 and December 31, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 11:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 2,459 | $9.92 | $24,396.23 |
DisclosureSEC source: 0001209191-20-000005 · doc4.xml · nonDerivative · entry 2 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,753.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.92 to $9.9238, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 11:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 4,640 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-000005 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,212.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 11:32 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 4,310 | $10.49 | $45,214.49 |
DisclosureSEC source: 0001209191-19-058620 · doc4.xml · nonDerivative · entry 2 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,572.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.490 to $10.495, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 30, 2019 Filed Dec 3, 2019 11:32 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 8,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-058620 · doc4.xml · derivative · entry 3 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on November 30, 2016, with 2,711 vesting on November 30, 2018 and 8,133 vesting on November 30, 2019. F6 · derivative.expiration_date: Restricted share units were granted on November 30, 2016, with 2,711 vesting on November 30, 2018 and 8,133 vesting on November 30, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 30, 2019 Filed Dec 3, 2019 11:32 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 8,133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-058620 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,882.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 12:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 93 | $16.63 | $1,546.13 |
DisclosureSEC source: 0001209191-19-020157 · doc4.xml · nonDerivative · entry 4 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,749.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.5800 to $16.6800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 12:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 263 | $16.63 | $4,372.40 |
DisclosureSEC source: 0001209191-19-020157 · doc4.xml · nonDerivative · entry 3 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,842.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.5800 to $16.6800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2019 Filed Mar 19, 2019 12:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 265 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-020157 · doc4.xml · derivative · entry 6 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266 Underlying: Ordinary Shares · 265 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on September 9, 2016, with 265 vesting on each of March 17, 2018 and March 17, 2019 and 266 vesting on March 17, 2020. F7 · derivative.expiration_date: Restricted share units were granted on September 9, 2016, with 265 vesting on each of March 17, 2018 and March 17, 2019 and 266 vesting on March 17, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 17, 2019 Filed Mar 19, 2019 12:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 747 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-020157 · doc4.xml · derivative · entry 5 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 748 Underlying: Ordinary Shares · 747 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on August 2, 2016, with 747 vesting on each of March 17, 2018 and March 17, 2019 and 748 vesting on March 17, 2020. F6 · derivative.expiration_date: Restricted share units were granted on August 2, 2016, with 747 vesting on each of March 17, 2018 and March 17, 2019 and 748 vesting on March 17, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 17, 2019 Filed Mar 19, 2019 12:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 265 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-020157 · doc4.xml · nonDerivative · entry 2 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,105.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 17, 2019 Filed Mar 19, 2019 12:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 747 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-020157 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,840.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 12:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,165 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016085 · doc4.xml · derivative · entry 3 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,165 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 4, 2015, with 1,165 vesting on each of March 4, 2018 and March 4, 2019. F6 · derivative.expiration_date: Restricted share units were granted on March 4, 2015, with 1,165 vesting on each of March 4, 2018 and March 4, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 12:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 409 | $16.88 | $6,905.27 |
DisclosureSEC source: 0001209191-19-016085 · doc4.xml · nonDerivative · entry 2 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,093.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.755 to $17.130, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 12:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,165 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-016085 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,502.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 12:14 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 56,716 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-017230 · doc4.xml · derivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,716 Underlying: Ordinary Shares · 56,716 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 18,905 vesting on each of March 4, 2021 and March 4, 2022 and 18,906 vesting on March 4, 2023. F2 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 18,905 vesting on each of March 4, 2021 and March 4, 2022 and 18,906 vesting on March 4, 2023. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 12:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 5,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-010837 · doc4.xml · derivative · entry 3 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,708 Underlying: Ordinary Shares · 5,353 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 14, 2017, with 5,353 vesting on each of February 14, 2019 and February 14, 2020 and 5,355 vesting on February 14, 2021. F6 · derivative.expiration_date: Restricted share units were granted on February 14, 2017, with 5,353 vesting on each of February 14, 2019 and February 14, 2020 and 5,355 vesting on February 14, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 12:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,841 | $17.67 | $32,528.63 |
DisclosureSEC source: 0001209191-19-010837 · doc4.xml · nonDerivative · entry 2 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,337.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.66 to $17.675, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 12:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 5,353 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-010837 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,178.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 12:24 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,643 | $15.70 | $25,799.21 |
DisclosureSEC source: 0001209191-19-000609 · doc4.xml · nonDerivative · entry 2 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,825.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.7 to $15.705, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 12:24 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 4,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-000609 · doc4.xml · derivative · entry 3 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,640 Underlying: Ordinary Shares · 4,640 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on July 1, 2014, with 4,640 vesting on each of December 31, 2018 and December 31, 2019. F6 · derivative.expiration_date: Restricted share units were granted on July 1, 2014, with 4,640 vesting on each of December 31, 2018 and December 31, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 12:24 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 4,640 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-000609 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,468.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 13:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 2,711 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-060707 · doc4.xml · derivative · entry 3 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,133 Underlying: Ordinary Shares · 2,711 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on November 30, 2016, with 2,711 vesting on November 30, 2018 and 8,133 vesting on November 30, 2019. F5 · derivative.expiration_date: Restricted share units were granted on November 30, 2016, with 2,711 vesting on November 30, 2018 and 8,133 vesting on November 30, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 13:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 933 | $21.76 | $20,304.04 |
DisclosureSEC source: 0001209191-18-060707 · doc4.xml · nonDerivative · entry 2 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,828.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.7600 to $21.7638, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 13:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 2,711 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-060707 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,761.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 20:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 91 | $17.88 | $1,626.90 |
DisclosureSEC source: 0001209191-18-020859 · doc4.xml · nonDerivative · entry 4 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,050.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.83 to $17.925, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 20:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 257 | $17.88 | $4,594.65 |
DisclosureSEC source: 0001209191-18-020859 · doc4.xml · nonDerivative · entry 3 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,141.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.83 to $17.925, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2018 Filed Mar 20, 2018 20:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 265 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-020859 · doc4.xml · derivative · entry 6 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 531 Underlying: Ordinary Shares · 265 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on September 9, 2016, with 265 vesting on each of March 17, 2018 and March 17, 2019 and 266 vesting on March 17, 2020. F6 · derivative.expiration_date: Restricted share units were granted on September 9, 2016, with 265 vesting on each of March 17, 2018 and March 17, 2019 and 266 vesting on March 17, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 17, 2018 Filed Mar 20, 2018 20:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 747 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-020859 · doc4.xml · derivative · entry 5 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,495 Underlying: Ordinary Shares · 747 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on August 2, 2016, with 747 vesting on each of March 17, 2018 and March 17, 2019 and 748 vesting on March 17, 2020. F5 · derivative.expiration_date: Restricted share units were granted on August 2, 2016, with 747 vesting on each of March 17, 2018 and March 17, 2019 and 748 vesting on March 17, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 17, 2018 Filed Mar 20, 2018 20:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 265 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-020859 · doc4.xml · nonDerivative · entry 2 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,398.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 17, 2018 Filed Mar 20, 2018 20:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 747 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-020859 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,133.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 3,432 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017207 · doc4.xml · derivative · entry 6 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,432 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on May 8, 2014 and vest on March 5, 2018. F4 · derivative.expiration_date: Restricted share units were granted on May 8, 2014 and vest on March 5, 2018. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Tax withholdingOrdinary Shares | 1,155 | $19.38 | $22,383.90 |
DisclosureSEC source: 0001209191-18-017207 · doc4.xml · nonDerivative · entry 4 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,386.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Tax withholdingOrdinary Shares | 400 | $19.38 | $7,752.00 |
DisclosureSEC source: 0001209191-18-017207 · doc4.xml · nonDerivative · entry 3 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,541.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 3,432 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-017207 · doc4.xml · nonDerivative · entry 2 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,941.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2018 Filed Mar 6, 2018 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,165 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017207 · doc4.xml · derivative · entry 5 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,165 Underlying: Ordinary Shares · 1,165 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 4, 2015, with 1,165 vesting on each of March 4, 2018 and March 4, 2019. F3 · derivative.expiration_date: Restricted share units were granted on March 4, 2015, with 1,165 vesting on each of March 4, 2018 and March 4, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2018 Filed Mar 6, 2018 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,165 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-017207 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,509.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:21 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 48,361 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009186 · doc4.xml · derivative · entry 2 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,361 Underlying: Ordinary Shares · 48,361 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022. F4 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:21 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantStock Options (right to buy) · Derivative | 123,288 | $0.00 Strike: $18.61 | $0.00 |
DisclosureSEC source: 0001209191-18-009186 · doc4.xml · derivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,288 Underlying: Ordinary Shares · 123,288 shares Expires 2028-02-08 F1 · derivative.exercise_date: Stock options were granted on February 9, 2018, with 41,096 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.